Scholars@Duke publication: The role of 1,25-dihydroxycholecalciferol (DHCC) in the pathogenesis and treatment of X-linked hypophosphatemic rickets (XLH)

The role of 1,25-dihydroxycholecalciferol (DHCC) in the pathogenesis and treatment of X-linked hypophosphatemic rickets (XLH)

Publication , Journal Article

Drezner, MK; Haussler, MR; Lyles, KW; Harrelson, JM

Published in: Clinical Research

January 1, 1979

Duke Scholars

Author Kenneth Ward Lyles Medicine, Geriatrics and Palliative Care

John Miles Harrelson

Author John Miles Harrelson Orthopaedic Surgery

Published In

Clinical Research

ISSN

0009-9279

Publication Date

January 1, 1979

Volume

27

Issue

2

Start / End Page

365

Citation

APA

Chicago

ICMJE

MLA

NLM

Drezner, M. K., Haussler, M. R., Lyles, K. W., & Harrelson, J. M. (1979). The role of 1,25-dihydroxycholecalciferol (DHCC) in the pathogenesis and treatment of X-linked hypophosphatemic rickets (XLH). Clinical Research, 27(2), 365.

Drezner, M. K., M. R. Haussler, K. W. Lyles, and J. M. Harrelson. “The role of 1,25-dihydroxycholecalciferol (DHCC) in the pathogenesis and treatment of X-linked hypophosphatemic rickets (XLH).” Clinical Research 27, no. 2 (January 1, 1979): 365.

Drezner MK, Haussler MR, Lyles KW, Harrelson JM. The role of 1,25-dihydroxycholecalciferol (DHCC) in the pathogenesis and treatment of X-linked hypophosphatemic rickets (XLH). Clinical Research. 1979 Jan 1;27(2):365.

Drezner, M. K., et al. “The role of 1,25-dihydroxycholecalciferol (DHCC) in the pathogenesis and treatment of X-linked hypophosphatemic rickets (XLH).” Clinical Research, vol. 27, no. 2, Jan. 1979, p. 365.

Drezner MK, Haussler MR, Lyles KW, Harrelson JM. The role of 1,25-dihydroxycholecalciferol (DHCC) in the pathogenesis and treatment of X-linked hypophosphatemic rickets (XLH). Clinical Research. 1979 Jan 1;27(2):365.

Published In

Clinical Research

ISSN

0009-9279

Publication Date

January 1, 1979

Volume

27

Issue

2

Start / End Page

365